Price to sales forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT
This article provides the "Price to sales forward" financial metric for Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT). It appears to be a financial data snippet from TradingView, without further elaborating on the value or implications of this metric. The content focuses on the company's financial data listing on the platform.
Comparative Analysis of Arcutis and Vertex Biotherapeutics
This article provides a comparative analysis of Arcutis Biotherapeutics and Vertex Pharmaceuticals based on their FY 2025 financial performance, market position, and future outlook. Arcutis showed significant revenue growth but faces stiff competition and patent litigation for its Zoryve product line, while Vertex demonstrated strong profitability and market dominance in rare disease treatments with substantial R&D investments. Analyst ratings suggest a positive outlook for Arcutis stock, despite recent price target downgrades.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics, Inc. announced the grant of 61,000 restricted stock units (RSUs) to 9 newly hired employees. These grants were made under the company's 2022 Inducement Plan, with a grant date of July 1, 2026, as a material inducement for their employment. The RSUs will vest over four years, with 25% vesting annually, subject to continued employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics, Inc. announced the grant of 61,000 restricted stock units (RSUs) to 9 new employees. These inducement grants were made under the company's 2022 Inducement Plan, with a grant date of July 1, 2026, and vest over four years. This action complies with Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment.
Arcutis lures 9 new hires with 61,000 stock awards
Arcutis Biotherapeutics (Nasdaq: ARQT) has granted an aggregate of 61,000 restricted stock units (RSUs) to nine new employees under its 2022 Inducement Plan. These awards, approved by the Board’s Compensation Committee, were granted on July 1, 2026, and will vest 25% annually over four years, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are intended as a material inducement for the new hires to join the company.
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36
Needham has reiterated its Buy rating for Arcutis Biotherapeutics (ARQT.US) and maintained its price target of $36. This indicates continued confidence in the company's stock performance and future prospects from the analyst firm.
Arcutis launches virtual dermatology platform for skin conditions
Arcutis Biotherapeutics has launched a virtual health platform to connect patients with board-certified dermatologists for chronic inflammatory skin conditions like eczema and psoriasis. This initiative aims to expand access to care, complementing traditional in-office visits, and facilitate the use of their ZORYVE portfolio. The company, with a market capitalization of $3.35 billion and strong revenue growth, is also highlighted for its impressive gross profit margins and predicted profitability this year by InvestingPro.
Should ZORYVE’s New Pediatric Label and Virtual Platform Expansion Require Action From Arcutis (ARQT) Investors?
Arcutis Biotherapeutics received FDA approval to extend ZORYVE cream treatment to children aged 2–5 and launched a virtual health platform to connect patients with dermatologists. This expansion supports Arcutis's revenue goals and broadens access to care, but investors should weigh the benefits against the concentration risk tied to ZORYVE. The company projects significant revenue and earnings growth by 2029, with a fair value estimate of $34.62, showcasing a potential 32% upside.
Arcutis launches virtual dermatology platform for skin conditions
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has launched a virtual health platform to connect patients with board-certified dermatologists for the evaluation and treatment of chronic inflammatory skin diseases like eczema, seborrheic dermatitis, and plaque psoriasis. This initiative aims to address barriers to in-person care and expand access to its ZORYVE portfolio for millions of Americans. The company emphasizes that clinical decision-making remains solely with the independent dermatologists.
Avoiding Lag: Real-Time Signals in (ARQT) Movement
The article provides a real-time analysis of Arcutis Biotherapeutics Inc. (NASDAQ: ARQT), highlighting a near-term neutral sentiment amid stronger mid and long-term outlooks. It details institutional trading strategies, including long and short setups with specific entry, target, and stop-loss levels, and presents a multi-timeframe signal analysis for support and resistance levels. The report emphasizes the use of AI-generated signals to avoid lag in trading decisions.
Arcutis Launches Virtual Dermatology Platform to Boost Access to Roflumilast
Arcutis Biotherapeutics is introducing a new virtual health platform to enhance access to its roflumilast (Zoryve) treatments for chronic inflammatory skin diseases like atopic dermatitis, seborrheic dermatitis, and plaque psoriasis. This platform connects individuals with independent, board-certified dermatologists through a streamlined digital experience, complementing traditional in-office care. The initiative aims to reduce barriers to specialist treatment and ensure timely access to care for patients.
Arcutis launches virtual dermatology platform for skin conditions By Investing.com
Arcutis Biotherapeutics has launched a virtual health platform connecting patients with board-certified dermatologists for chronic inflammatory skin diseases like eczema and psoriasis. The platform aims to address barriers to in-person care and expand access to diseases for the company's ZORYVE portfolio. Arcutis, a commercial-stage biopharmaceutical company, reported strong revenue growth and impressive gross profit margins, with analysts predicting profitability this year.
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
Arcutis Biotherapeutics has launched a new virtual health platform to improve access to care for individuals with chronic inflammatory skin diseases, including those eligible for ZORYVE. The platform connects patients with independent, board-certified dermatologists through a streamlined digital experience, complementing traditional in-office visits. This initiative aims to reduce barriers like long wait times and geographic limitations, ensuring more people can access timely specialist treatment and determine if ZORYVE is an appropriate option.
Arcutis Biotherapeutics Announces FDA Approval of Expanded ZORYVE Cream 0.3% Indication for Children With Plaque Psoriasis Down to Age 2
Arcutis Biotherapeutics announced FDA approval for ZORYVE cream 0.3% to treat plaque psoriasis in children as young as two, marking it as the first once-daily, non-steroidal topical treatment for this age group. This approval addresses a significant treatment gap, offering a safe and effective option for sensitive skin areas and long-term use. Supported by clinical studies, ZORYVE has received seven FDA approvals in four years and includes patient assistance programs to improve access.
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36
This article provides a quick look at today's analyst ratings for Arcutis Biotherapeutics (ARQT.US). The forecast for the company's stock is currently between $34 and $36, reflecting recent analyst insights. Investors can use this information to understand current market sentiment and potential price targets for ARQT.
Arcutis Biotherapeutics Inc Actuals & Estimates (NASDAQ:ARQT)
This article provides an overview of Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) financials, stock performance, and analyst forecasts. It covers key metrics such as current stock price, market capitalization, historical highs and lows, earnings per share, and revenue, alongside analyst price targets and recommendations. The report also includes frequently asked questions regarding ARQT stock.
ARQT Forecast — Price Target — Prediction for 2027
The article provides a forecast for Arcutis Biotherapeutics, Inc. (ARQT) stock, including analyst price targets, historical performance, and key financial metrics. It details the company's current stock price, market capitalization, earnings, and revenue, alongside general investment disclaimers.
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%
A director at Arcutis Biotherapeutics, Sue-Jean Lin, sold 4,946 shares of company stock worth $121,000, representing 15% of her direct holdings. This transaction was executed under a pre-arranged 10b5-1 trading plan, indicating routine portfolio management rather than a warning sign. Meanwhile, Arcutis's ZORYVE franchise saw a 65% increase in first-quarter net product revenue, driven by strong prescription growth, and the company provided positive full-year revenue guidance.
Discipline and Rules-Based Execution in ARQT Response
This article analyzes Arcutis Biotherapeutics Inc. (NASDAQ: ARQT), highlighting strong sentiment and an overweight bias across all horizons. It presents three AI-generated trading strategies with specific entry, target, and stop-loss levels for different risk profiles. The analysis also identifies key support and resistance levels across near-term, mid-term, and long-term timeframes.
Insider Sell Alert: Sue-jean Lin Sells Shares of Arcutis Biotherapeutics Inc (ARQT)
Sue-jean Lin, a Director at Arcutis Biotherapeutics Inc (ARQT), sold 4,946 shares of the company on June 15, 2026. This transaction brings her total holdings to 27,567 shares. Over the past year, there have been 58 insider sells and 0 insider buys for ARQT, with Lin having sold a total of 30,218 shares. Currently, ARQT is considered modestly undervalued with a price-to-GF-Value ratio of 0.82.
Arcutis (ARQT) director Sue-Jean Lin executes planned share sale
Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares of common stock at a weighted average price of $24.38 per share. This transaction was part of a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2025. Following the sale, Ms. Lin directly holds 27,567 shares of the company.
Arcutis Biotherapeutics Inc (ARQT) Earnings Forecast: Future EPS & Revenue Growth Estimates
Arcutis Biotherapeutics Inc (ARQT) has an earnings forecast score of 8.25, ranking 48th in the Pharmaceuticals industry. Analysts have a consensus price target of $30.50, with ratings predominantly suggesting a "Buy." The company's expected revenue for the next quarter is $117.54 million, with an anticipated EPS of $0.03.
Arcutis Biotherapeutics Inc (ARQT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Arcutis Biotherapeutics Inc (ARQT) focusing on its dividend and stock split history. It states that the company has not distributed any dividends over the past five years and shows no record of stock splits. The page also displays current stock quotes and market capitalization for ARQT.
Howard Welgus sells 21,240 ARQT shares (NASDAQ: ARQT)
Howard Welgus, an insider at Arcutis Biotherapeutics (NASDAQ: ARQT), reported the sale of a total of 21,240 shares across three dates in 2026, with proceeds listed for each transaction. The filing also noted a 635-share restricted stock vesting. This Form 144 disclosure provides details on the shares sold and their corresponding proceeds but does not include the rationale or timing for these sales.
[144] Arcutis Biotherapeutics, Inc. SEC Filing
Arcutis Biotherapeutics, Inc. has filed a Form 144 notice to sell 4,096 shares of Common Stock, with the filing dated June 15, 2026. This filing details underlying stock option exercises and notes two recent sales by Howard Welgus in April and May 2026. The Form 144 provides transparency on proposed insider sales and relevant financial activities.
Arcutis (ARQT) director amends filing to correct indirect share count
Arcutis Biotherapeutics director Patrick J. Heron filed an amended insider report (Form 4/A) to correct an understatement of his indirect share holdings. A previous Form 4 had inadvertently understated the common shares he indirectly held through Frazier Life Sciences X, L.P. by 2,646 shares due to a scrivener's error. The corrected filing now reports 27,448 indirectly held shares, with Heron disclaiming beneficial ownership beyond his pecuniary interest.
Arcutis Biotherapeutics, Inc. (ARQT) reports Q1 loss, beats revenue estimates
Arcutis Biotherapeutics, Inc. (ARQT) reported a loss of $0.85 per share for the first quarter of 2026, which is narrower than the Zacks Consensus Estimate of a $0.94 loss. The company's quarterly revenues of $57.07 million exceeded the Zacks Consensus Estimate by 29.83% and significantly surpassed the $18.42 million reported in the prior year's quarter. This strong revenue performance was driven primarily by sales of ZORYVE.
Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy?
Arcutis Biotherapeutics (ARQT) is focusing on education regarding genital psoriasis, highlighted by a recently published consortium manuscript, to broaden its dermatology strategy. This initiative, combined with strong recommendations for its ZORYVE product in pediatric atopic dermatitis, reinforces the company's commitment to under-recognized skin conditions. However, investors should note the company's significant reliance on the ZORYVE franchise for its projected revenue growth and potential earnings increases.
GW&K Investment Management LLC Sells 163,461 Shares of Arcutis Biotherapeutics, Inc. $ARQT
GW&K Investment Management LLC reduced its stake in Arcutis Biotherapeutics (NASDAQ:ARQT) by 13.9% in the fourth quarter, selling 163,461 shares. Despite this, analysts maintain a "Moderate Buy" rating for ARQT with an average price target of $34.00. The company reported quarterly revenues exceeding estimates but missed EPS expectations, and several insiders, including the CEO and CFO, sold shares to cover tax obligations.
Is Arcutis Biotherapeutics (ARQT) Quietly Redefining Its Risk Profile With ZORYVE Momentum And New Guidance?
Arcutis Biotherapeutics (ARQT) is showing ZORYVE momentum and moving towards a self-sustaining financial position, supported by new expert guidance on genital psoriasis. The company's focus on underserved dermatology niches and upcoming regulatory milestones for ZORYVE pediatric and infant labels are key to its investment narrative. Despite this progress, the company faces concentration risk if ZORYVE underperforms or new non-steroidal options gain market share.
Is Arcutis Biotherapeutics (ARQT) Quietly Redefining Its Risk Profile With ZORYVE Momentum And New Guidance?
Arcutis Biotherapeutics (ARQT) is strengthening its investment narrative through continued ZORYVE momentum, upcoming regulatory milestones, and achieving a self-sustaining financial position. The company is actively focusing on underserved dermatology niches, including genital psoriasis and pediatric applications of ZORYVE. While offering significant upside potential with a fair value estimate of $34.62, investors should remain aware of the inherent risk due to the company's concentration in the ZORYVE franchise.
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.
Rep. Gilbert Ray Cisneros, Jr. recently purchased shares of Arcutis Biotherapeutics (NASDAQ:ARQT) worth between $1,001 and $15,000 on May 29th, according to a June 8th filing. This purchase occurred despite Arcutis Biotherapeutics missing Q1 EPS expectations, though revenue slightly exceeded estimates. Analysts maintain a "Moderate Buy" consensus for ARQT with an average target price of $34.
[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity
Arcutis Biotherapeutics director Patrick J. Heron reported new equity awards, including 5,778 Restricted Stock Units and a stock option for 16,667 shares. These awards are in connection with his service as a non-employee director and will vest based on continued service. Heron's total holdings now include 32,213 direct shares and indirect interests in shares held by various Frazier Life Sciences entities and The Heron Living Trust.
[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity
This article details an insider trading activity for Arcutis Biotherapeutics, Inc. (ARQT) involving Director Leonard Keith R, as reported in a Form 4 filing. The summary indicates three reported transactions with a neutral impact and sentiment. The transactions include grants of stock options and common stock, along with existing holdings by the director and a family trust.
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status
Arcutis Biotherapeutics (ARQT) reports strong growth for its drug ZORYVE and expects several regulatory and clinical milestones, including potential FDA approvals for ZORYVE in pediatric psoriasis and atopic dermatitis. The company emphasized its new cash-flow positive status, which will support continued investment in ZORYVE indications and broader R&D efforts. Arcutis also discussed its commercial strategy, pipeline, and efforts to expand ZORYVE's use and access, particularly focusing on conversion from topical steroids and growth in Medicare.
Arcutis Biotherapeutics (ARQT) 2026 meeting OKs directors, auditor and executive pay
Arcutis Biotherapeutics (ARQT) shareholders approved all three proposals at their 2026 Annual Meeting, held on June 5, 2026. This included the election of three Class III directors, the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2026, and the advisory approval of executive officer compensation. Additionally, the Board approved revisions to the Non-Employee Director Compensation Program.
Geode Capital Management LLC Has $79.97 Million Stock Holdings in Arcutis Biotherapeutics, Inc. $ARQT
Geode Capital Management LLC increased its stake in Arcutis Biotherapeutics (NASDAQ:ARQT) by 5.6% in the fourth quarter, now holding 2.75 million shares valued at $79.97 million. Despite missing analyst EPS expectations, Arcutis's revenue slightly exceeded estimates. Analysts maintain a "Moderate Buy" consensus with an average price target of $34.00, though some recent ratings have been cautious.
Assessing Arcutis Biotherapeutics (ARQT) Valuation After New Genital Psoriasis Clinical Guidance Publication
Arcutis Biotherapeutics (ARQT) is being re-evaluated after supporting new clinical guidance for genital psoriasis, despite its stock price falling 27% year-to-date. The company's valuation narrative suggests it is 46.9% undervalued, with a fair value of $39.99 per share, largely due to the potential of its drug ZORYVE. Investors are encouraged to consider the execution and funding risks associated with ZORYVE's uptake.
Six new Arcutis hires receive 44,000 restricted stock units
Arcutis Biotherapeutics (Nasdaq: ARQT) has granted a total of 44,000 restricted stock units (RSUs) to six new employees under its 2022 Inducement Plan. These RSUs, effective June 1, 2026, will vest over four years, with 25% vesting annually, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants serve as a material inducement for the new hires joining the company.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the grant of 44,000 restricted stock units to six new employees under its 2022 Inducement Plan. These awards, granted on June 1, 2026, are a material inducement for their employment, vesting over four years, and are reported in accordance with Nasdaq Listing Rule 5635(c)(4). Arcutis is a commercial-stage biopharmaceutical company focused on immuno-dermatology.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics, Inc. announced the grant of 44,000 restricted stock units to six new employees as an inducement to their employment. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest over four years, with 25 percent vesting annually, contingent on continuous employment.
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis
A new expert consensus, published in the American Journal of Clinical Dermatology and developed by the Genital Psoriasis Wellness Consortium, offers age-specific guidance for the diagnosis and management of genital psoriasis. This second publication from the Consortium emphasizes routine assessment, empathetic communication, and individualized treatment approaches to address gaps in care for this often-overlooked condition affecting approximately two-thirds of plaque psoriasis patients. The recommendations aim to improve early diagnosis, patient engagement, and personalized dermatologic care across pediatric, adult, and older populations.
New age-based genital psoriasis guidelines target missed diagnoses
Arcutis Biotherapeutics (NASDAQ: ARQT) has announced the publication of new expert consensus guidance for improving care in individuals with genital psoriasis. Developed by the Arcutis-supported Genital Psoriasis Wellness Consortium, the guidance provides age-specific recommendations for pediatric, adult, and older patients, aiming to address missed diagnoses and undertreatment of this common condition. It emphasizes routine genital assessment, empathetic communication, and individualized treatment approaches, including minimizing long-term topical corticosteroid use.
ARQT Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Arcutis Biotherapeutics Inc. (ARQT) financials, focusing on revenue breakdown, profitability margins, and a comparison with competitors. ARQT boasts a high gross margin of 90.72% but records negative operating and net margins. The company's market capitalization is $2.68B, and its efficiency is benchmarked against industry leaders like IDYA and TARS.
Hillsdale Investment Management Inc. Invests $5.21 Million in Arcutis Biotherapeutics, Inc. $ARQT
Hillsdale Investment Management Inc. has acquired a new position in Arcutis Biotherapeutics (NASDAQ:ARQT), purchasing 179,420 shares valued at approximately $5.21 million during the fourth quarter. Other institutional investors have also adjusted their holdings in the company. Despite Arcutis Biotherapeutics missing analyst earnings estimates for the recent quarter, revenue slightly exceeded expectations, and Wall Street maintains a "Moderate Buy" consensus rating with an average price target of $34.
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Arcutis Biotherapeutics, Inc. announced that its management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference, scheduled for June 8-10, 2026, in Miami. A fireside chat will be held on June 9, 2026, at 2:00 p.m. ET, with a webcast available on the company's website. Arcutis is a commercial-stage biopharmaceutical company focused on immuno-dermatology, with a portfolio of approved targeted topicals and a robust pipeline for inflammatory dermatological conditions.
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Arcutis Biotherapeutics, Inc. announced that its management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference, scheduled for June 8-10, 2026, in Miami. A fireside chat will take place on June 9, 2026, at 2:00 p.m. ET, with a webcast made available on the company’s website. Arcutis is a commercial-stage biopharmaceutical company focused on immuno-dermatology innovations.
Biotech Arcutis joins Goldman Sachs healthcare talks in Miami, streaming online
Arcutis Biotherapeutics (NASDAQ: ARQT) announced its management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami from June 8-10, 2026. A fireside chat is scheduled for June 9, 2026, at 2:00 p.m. ET, with a webcast available for 180 days on the company's website. This presentation follows recent positive clinical and regulatory updates for their product ZORYVE, alongside varied reactions to financial reports.
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Arcutis Biotherapeutics, Inc. announced that its management will present at the Goldman Sachs 47th Annual Global Healthcare Conference, taking place from June 8-10, 2026, in Miami. The fireside chat is scheduled for Tuesday, June 9, 2026, at 2:00 p.m. ET, and a webcast will be available on the company's website. Arcutis is a commercial-stage biopharmaceutical company focused on immuno-dermatology, developing treatments for immune-mediated dermatological diseases.
Insiders At Arcutis Biotherapeutics Sold US$4.4m In Stock, Alluding To Potential Weakness
Insiders at Arcutis Biotherapeutics (NASDAQ: ARQT) have sold US$4.4 million worth of stock over the last year, indicating potential concerns about the company's future performance. This significant insider selling, particularly a large single sale, suggests that those with intimate knowledge of the company may perceive the stock to be overvalued or anticipate future challenges.
